Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC).

被引：3
|
作者：
Santiago-Walker, Ademi E.
Moy, Christopher
Cherkas, Yauheniya
Loriot, Yohann
Siefker-Radtke, Arlene O.
Motley, Clifford
Avadhani, Anjali Narayan
OHagan, Anne
De Porre, Peter
Lorenzi, Matthew V.
McCaffery, Ian
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Inst Cancerol Gustave Roussy, Villejuif, France
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Janssen Res & Dev, Beerse, Belgium
[5] Janssen Res & Dev LLC, Raritan, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
420
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
    Siefker-Radtke, A. O.
    Loriot, Y.
    Necchi, A.
    Huddart, R. A.
    Burgess, E. F.
    Rezazadeh, A.
    O'Hagan, A.
    De Porre, P.
    Avadhani, A.
    Monga, M.
    Cherkas, Y.
    Moy, C. H.
    Santiago-Walker, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S584
  • [2] Urothelial Carcinoma: Gene Analysis of Tumor-tissue and circulating Tumor-DNA
    不详
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (01) : 13 - 14
  • [3] Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.
    Vandekerkhove, Gillian
    Lavoie, Jean-Michel
    Annala, Matti
    Sundahl, Nora
    Sano, Takeshi
    Struss, Werner J.
    Todenhofer, Tilman
    Ost, Piet
    Chi, Kim N.
    Black, Peter C.
    Eigl, Bernhard J.
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Circulating Tumor DNA (ctDNA) in Urothelial Carcinoma-the long-desired Biomarker?
    Grunewald, C. Marisa
    Niegisch, G.
    UROLOGE, 2021, 60 (11): : 1466 - 1467
  • [5] Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial
    Powles, Thomas
    Chang, Wayne Yen-Hwa
    Yamamoto, Yoshiaki
    Munoz-Langa, Jose
    Reyes, Felipe
    Peer, Avivit
    Yu, Evan Y.
    Cohen, Graham
    Lorch, Anja
    Bavle, Abhishek
    Moreno, Blanca Homet
    Markensohn, Julia
    Edmondson, Mackenzie
    Chen, Cai
    Cristescu, Razvan
    Pena, Carol Elaine
    Lunceford, Jared
    Gunduz, Seyda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.
    Schonlau, Elena
    Mueller, David Christian
    Vandekerkhove, Gillian
    Murtha, Andrew
    Bacon, Jack V. W.
    Wells, Connor
    Rostin, Kimia
    Parimi, Sunil
    Noonan, Krista
    Basappa, Naveen S.
    Ko, Jenny J.
    Finch, Daygen L.
    Alimohamed, Nimira S.
    Bismar, Tarek A.
    Nappi, Lucia
    Annala, Matti
    Bernales, Cecily Q.
    Chi, Kim N.
    Wyatt, Alexander William
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study.
    Chen Haige
    Zhang Ruiyun
    Xie Feng
    Du Pan
    Zhang Yue
    Jia Shidong
    Zhuang Guanglei
    Huang Yiran
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Determination of Circulating tumor DNA alterations in advanced urothelial carcinoma patients treated with pembrolizumab
    Tanuma, Kozaburo
    Kojima, Takahiro
    Shiga, Masanobu
    Kandori, Shuya
    Kimura, Tomokazu
    Kawahara, Takashi
    Negoro, Hiromitsu
    Nishiyama, Hiroyuki
    CANCER SCIENCE, 2021, 112 : 872 - 872
  • [9] Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study
    Imkamp, Florian
    Loriot, Yohann
    Necchi, Andrea
    Park, Se Hoon
    Huddart, Robert
    Burgess, Earle
    Fu, Min
    Santiago-Walker, Ademi
    Mukhopadhyay, Sutapa
    Naini, Vahid
    Deprince, Kris
    Monga, Manish
    Siefker-Radtke, Arlene
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 78 - 78
  • [10] Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study
    Loriot, Y.
    Necchi, A.
    Park, S. H.
    Huddart, R. A.
    Burgess, E.
    Zhong, B.
    Santiago-Walker, A.
    Little, S.
    Roccia, T.
    De Porre, P.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2018, 29
12345